365 related articles for article (PubMed ID: 28504191)
1. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
[TBL] [Abstract][Full Text] [Related]
2. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
3. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft SC; Weiss AA
Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
[TBL] [Abstract][Full Text] [Related]
5. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.
Crowe SR; Garman L; Engler RJ; Farris AD; Ballard JD; Harley JB; James JA
Vaccine; 2011 May; 29(20):3670-8. PubMed ID: 21420416
[TBL] [Abstract][Full Text] [Related]
6. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.
Clement KH; Rudge TL; Mayfield HJ; Carlton LA; Hester A; Niemuth NA; Sabourin CL; Brys AM; Quinn CP
Clin Vaccine Immunol; 2010 Nov; 17(11):1753-62. PubMed ID: 20739500
[TBL] [Abstract][Full Text] [Related]
8. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
[TBL] [Abstract][Full Text] [Related]
9. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
[TBL] [Abstract][Full Text] [Related]
10. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD
PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
12. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.
Chi X; Li J; Liu W; Wang X; Yin K; Liu J; Zai X; Li L; Song X; Zhang J; Zhang X; Yin Y; Fu L; Xu J; Yu C; Chen W
Clin Vaccine Immunol; 2015 May; 22(5):553-60. PubMed ID: 25787135
[TBL] [Abstract][Full Text] [Related]
13. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
Welkos S; Little S; Friedlander A; Fritz D; Fellows P
Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
[TBL] [Abstract][Full Text] [Related]
14. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
16. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
[TBL] [Abstract][Full Text] [Related]
17. [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice].
Wang X; Chi X; Liu J; Liu W; Liu S; Qiu S; Wen Z; Fan P; Liu K; Song X; Fu L; Zhang J; Yu C
Sheng Wu Gong Cheng Xue Bao; 2016 Nov; 32(11):1590-1599. PubMed ID: 29034628
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the human immune response to the UK anthrax vaccine.
Baillie L; Townend T; Walker N; Eriksson U; Williamson D
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
[TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
[TBL] [Abstract][Full Text] [Related]
20. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]